Hypertension, Phase III

TARGET BP I Clinical Trial (TARGET BP I)

Volunteers
Health Professionals

What is the purpose of this trial?

Brief Summary:

The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group (without renal denervation - no alcohol infusion). Subjects will be randomized in a 1:1 fashion to treatment versus sham control via central randomization

Trial with
Ablative Solutions, Inc.
Ages
18 years - 80 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Juan Carmona

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Carlos Mena-Hurtado, MD, FACC, FSCAI, FAHA
Associate Professor of Medicine (Cardiology); Director CME, Section of Cardiology, Internal Medicine; Co-Director Limb Preservation Program, Yale New Haven Health System; Co-Director Vascular Outcomes Program, Internal Medicine; Primary Member, Yale Institutional Review Board; Member, Yale School of Medicine Progress Committee; Medical Director Vascular Medicine - YNHH, Internal Medicine; Honorary Clinical Reader in Centre, Clinical Pharmacology in the William Harvey Research Institute, Queen Mary University; Consultant, Center For Devices and Radiological Health, U.S. Food and Drug Administration; Interventional Cardiology Item-Writing Task Force, Task Force, American Board Of Internal Medicine

Sub-Investigator

Jeffrey Turner, MD

Last Updated
10/04/2024
Study HIC
#2000025879